Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 9 | Journal of Experimental & Clinical Cancer Research

Fig. 9

From: Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence

Fig. 9

FL118 preferentially inhibits AR−/lo LAPC9-AI cells in organoid screening assays: A Experimental schema. LAPC9-AD/AI cells were purified out from the maintenance tumors. Cytotoxic/cytostatic effects of drug (FL118) treatment were measured using resazurin assays in triplicate culture (5,000 cells/well in 96-well plate). B Representative LAPC9-AD and LAPC9-AI organoid images 6 days after FL118 treatment. C, D FL118 exhibited a more prominent inhibitory effect on AR−/lo LAPC9 than AR.+ LAPC9-AD organoids. Shown in C are bar graphs of LAPC9-AD (top) and LAPC9-AI (bottom) organoids in the presence of vehicle control (DMSO) or increasing concentrations of FL118. Data are normalized to DMSO-treated control samples and presented as mean ± SD. Shown in D are the dose–response curves generated using relative viable cell numbers after treatment with increasing concentrations of FL118 for 4 days. The inhibitory effects (IC50) of FL118 on LAPC9-AI compared to LAPC9-AD are statistically highly significant (P < 0.0001; two-way ANOVA)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us